Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Primary Biliary Cholangitis Clear all
Active, not recruiting Phase 3 Interventional

Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

NCT03301506
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Seladelpar 5 mg Capsule, Seladelpar 10 mg Capsule
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
40
States / cities
Little Rock, Arkansas • Palo Alto, California • Pasadena, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 21, 2026, 6:57 PM EDT
Completed Phase 1 Interventional

A Pilot Study of Xifaxan to Treat Patients With PSC

NCT01695174
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
Xifaxan
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Jul 21, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Results available

A Study of NGM282 in Patients With Primary Sclerosing Cholangitis

NCT02704364
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
NGM282, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
26
States / cities
Sacramento, California • San Clemente, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Jul 21, 2026, 6:57 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

NCT03155932
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
APD334
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Sacramento, California • Houston, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Jul 21, 2026, 6:57 PM EDT
Recruiting No phase listed Observational

A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

NCT06447168
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Not listed
Lead sponsor
Ipsen
Industry
Eligibility
Not listed
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
20
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 21, 2026, 6:57 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

NCT03183570
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, Covid19 Pneumonia
Interventions
[18F]FP-R01-MG-F2
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jul 21, 2026, 6:57 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis

NCT01088607
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
ursodeoxycholic acid (UDCA)
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
5 Years to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Jul 21, 2026, 6:57 PM EDT
Completed Phase 3 Interventional

Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis

NCT00805805
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Tetrathiomolybdate, Placebo
Drug · Other
Lead sponsor
George Brewer
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jul 21, 2026, 6:57 PM EDT
Completed Phase 2Phase 3 Interventional

Study of Combivir for Patients With Primary Biliary Cirrhosis

NCT00490620
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Combination antiviral therapy, Placebo
Drug
Lead sponsor
University of Alberta
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 31, 2007 · Synced Jul 21, 2026, 6:57 PM EDT
Recruiting No phase listed Observational

MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease

NCT03178630
View directory record Official record
Conditions
Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 23 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Jul 21, 2026, 6:57 PM EDT
Completed Phase 2Phase 3 Interventional

Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

NCT05133336
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 21, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

NCT04480840
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
PLN-74809, Placebo
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
21
States / cities
Pasadena, California • Redwood City, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 21, 2026, 6:57 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

NCT06247735
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
K-808 (Dose A), K-808 (Dose B), Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Tucson, Arizona • Coronado, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 21, 2026, 6:57 PM EDT
Completed Not applicable Interventional

A Pilot Study Examining Diet in Primary Sclerosing Cholangitis

NCT04678219
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Dietary Intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jul 21, 2026, 6:57 PM EDT
Terminated Not applicable Interventional

Mindfulness - Based Intervention in the Treatment of Fatigue in Patients With Primary Biliary Cholangitis

NCT03684187
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Mindfulness Based Intervention
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Jul 21, 2026, 6:57 PM EDT
Completed Phase 3 Interventional

Ursodiol-Methotrexate for Primary Biliary Cirrhosis

NCT00006168
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
Methotrexate
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
20 Years to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2004
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Jul 21, 2026, 6:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis (PSC)

NCT02978339
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Curcumin
Drug
Lead sponsor
John E. Eaton
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jul 21, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

NCT01865812
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Obeticholic Acid
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Jul 21, 2026, 6:57 PM EDT
Recruiting Phase 2 Interventional

Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation

NCT06905054
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Liver Transplant, Complications, PSC, Biliary Strictures
Interventions
Fenofibrate (drug), Blood draw for the laboratory assessment, MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 21, 2026, 6:57 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis

NCT00406237
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
tigecycline
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Saint Paul, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2011 · Synced Jul 21, 2026, 6:57 PM EDT
Recruiting Phase 1 Interventional

A Study of SIPLIZUMAB in AILD and LT Patients

NCT06455280
View directory record Official record
Conditions
Autoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, End Stage Liver DIsease, Cirrhosis, Liver
Interventions
Siplizumab
Drug
Lead sponsor
Elizabeth C. Verna
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jul 21, 2026, 6:57 PM EDT
Completed Not applicable Interventional

Quality of Life in Patients With Primary Sclerosing Cholangitis

NCT02712736
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
quality of life survey
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Jul 21, 2026, 6:57 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

NCT04526665
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Elafibranor 80mg, Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
46
States / cities
Chandler, Arizona • Los Angeles, California • Sacramento, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 21, 2026, 6:57 PM EDT
Terminated Phase 3 Interventional Results available

To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate

NCT06488911
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
FDC tablet (OCA 5 mg + BZF 400 mg SR)
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Coronado, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 21, 2026, 6:57 PM EDT